
### ICB_Wolf2

- **Read Paper:** [Durvalumab with Olaparib and Paclitaxel for High-Risk HER2-Negative Stage II/III Breast Cancer: Results from the Adaptively Randomized I-SPY2 Platform Trial](https://pubmed.ncbi.nlm.nih.gov/34143979) (PMID: 34143979)
- **Objective:** Evaluate the efficacy and molecular predictors of response to the combination therapy of durvalumab, olaparib, and paclitaxel in high-risk HER2-negative stage II/III breast cancer.
- **Clinical Data:** [GSE173839_ISPY2_DurvalumabOlaparibArm_biomarkers.csv.gz](https://ftp.ncbi.nlm.nih.gov/geo/series/GSE173839/GSE173839_ISPY2_DurvalumabOlaparibArm_biomarkers.csv.gz)
- **Processed Data:** [GSE173839_ISPY2_AgilentGeneExp_durvaPlusCtr_FFPE_meanCol_geneLevel_n105.txt.gz](https://ftp.ncbi.nlm.nih.gov/geo/series/GSE173839/GSE173839_ISPY2_AgilentGeneExp_durvaPlusCtr_FFPE_meanCol_geneLevel_n105.txt.gz)
- **GEO Accession Number:** [GSE173839](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE173839)

---
